secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2026-07-30T10:15:42+00:00
Accession:  0001723128-26-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q2 net revenue $796M (+10% YoY); GAAP EPS $0.18; raises FY 2026 guidance
-------------------------------------------------------------------------------

- Net revenue $796M (+10% YoY); GAAP net income $58M, diluted EPS $0.18 (vs $0.07 YoY).
- Adjusted EBITDA $206M (+12% YoY); adjusted diluted EPS $0.30 (+20% YoY).
- Specialty revenue +17% driven by CREXONT, BREKIYA, UNITHROID; Affordable Medicines +13% on complex portfolio.
- Raising full-year 2026 guidance for second time this year; debt repricing in July reduces interest cost.
- Pending Kashiv transaction to establish biosimilars as new growth vertical.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/0001723128-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001723128-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer